Search Results

Showing results 2111 - 2120 for weill cornell connect patient portal

Iron Chelators for the Treatment of Adult Neuronal Ceroid Lipofuscinosis | Enterprise Innovation

.... Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed to providing...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/iron-chelators-treatment-adult-neuronal-ceroid

Irreversible S1PR2 Antagonists for the Treatment of Inflammation and Fibrosis | Enterprise Innovation

.... With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/irreversible-s1pr2-antagonists-treatment

Tumor-Derived Exomeres as Biomarkers for Cancer Detection and Monitoring | Enterprise Innovation

... Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/tumor-derived-exomeres-biomarkers-cancer-detection

Using Deferiprone to Target Mitochondrial Iron for the Treatment of Pulmonary Diseases | Enterprise Innovation

... Events Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/using-deferiprone-target-mitochondrial-iron

Synthesis of RNAs Containing Methylated Adenosine Residues and Their Use in Enhancing Translation | Enterprise Innovation

... Past Events Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/synthesis-rnas-containing-methylated-adenosine

MicroRNA Expression Levels are Predictive of Human Allograft Status | Enterprise Innovation

... Ecosystem menu options BioVenture eLab Center for Technology Licensing at Weill Cornell Medicine Weill...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/microrna-expression-levels-are-predictive-human

NRDG1-ERG, A Novel Fusion Protein in Prostate Cancer | Enterprise Innovation

.... Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/nrdg1-erg-novel-fusion-protein-prostate-cancer

SLC45A3-ELK4 as a Non-invasive Diagnostic Marker for Prostate Cancer | Enterprise Innovation

... of putting patients first, Weill Cornell Medicine is committed to providing exemplary...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/slc45a3-elk4-non-invasive-diagnostic-marker

Methods for the Efficient Identification of Ubiquitination Sites by Proteomics | Enterprise Innovation

... Care. Discover. Teach. With a legacy of putting patients first, Weill Cornell Medicine is committed...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/methods-efficient-identification-ubiquitination

Novel Target and Inhibitors for prevention and treatment of Tuberculosis | Enterprise Innovation

... of putting patients first, Weill Cornell Medicine is committed to providing exemplary and individualized...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/novel-target-and-inhibitors-prevention-and

Showing results 2111 - 2120 for weill cornell connect patient portal